Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercoagulable states and strokes.

Nena Matijevic, Kenneth K Wu

    Current Atherosclerosis Reports
    |July 11, 2006
    PubMed
    Summary
    This summary is machine-generated.

    Hematologic disorders like essential thrombocythemia increase ischemic stroke risk by causing a hypercoagulable state. While some hemostatic defects are linked to stroke, their predictive value and causal role require further investigation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Smooth muscle-specific expression of hydroxyindole O-methyltransferase reduces arterial injury-induced intimal hyperplasia.

    Journal of biomedical science·2025
    Same author

    5-Methoxytryptophan attenuates oxidative stress-induced downregulation of PINK1 and mitigates mitochondrial damage and apoptosis in cardiac myocytes.

    Free radical biology & medicine·2025
    Same author

    5-Methoxytryptophan Protects against Toll-Like Receptor 2-Mediated Renal Tissue Inflammation and Fibrosis in a Murine Unilateral Ureteral Obstruction Model.

    Journal of innate immunity·2025
    Same author

    Extracellular Succinate: A Physiological Messenger and a Pathological Trigger.

    International journal of molecular sciences·2023
    Same author

    Cancer-derived extracellular succinate: a driver of cancer metastasis.

    Journal of biomedical science·2022
    Same author

    Control of Tissue Fibrosis by 5-Methoxytryptophan, an Innate Anti-Inflammatory Metabolite.

    Frontiers in pharmacology·2021
    Same journal

    The Spectrum of Genetic Causes of Familial Hypercholesterolemia Phenotype.

    Current atherosclerosis reports·2026
    Same journal

    Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.

    Current atherosclerosis reports·2026
    Same journal

    Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review.

    Current atherosclerosis reports·2026
    Same journal

    Artificial and Other Non-Nutritive Sweeteners, the Microbiome, and Cardiometabolic Health.

    Current atherosclerosis reports·2026
    Same journal

    Single-cell Technologies in Atherosclerosis: Uncovering Cellular Heterogeneity, Mechanisms, and Therapeutic Opportunities.

    Current atherosclerosis reports·2026
    Same journal

    Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.

    Current atherosclerosis reports·2026
    See all related articles

    Area of Science:

    • Hematology
    • Neurology
    • Vascular Medicine

    Background:

    • Hematologic disorders and hemostatic defects are known risk factors for ischemic stroke.
    • A common underlying mechanism is a prothrombotic or hypercoagulable state.

    Purpose of the Study:

    • To review hematologic disorders that clearly cause stroke.
    • To discuss the investigational association of hemostatic defects with stroke risk.

    Main Methods:

    • Literature review of hematologic conditions and hemostatic factors associated with ischemic stroke.
    • Analysis of established causes versus investigational associations.

    Main Results:

    • Essential thrombocythemia, polycythemia vera, and thrombotic thrombocytopenic purpura are confirmed causes of stroke with available treatments.

    Related Experiment Videos

  • Several hemostatic factors (e.g., soluble thrombomodulin, fibrinogen, factor VIII) are associated with stroke risk, but their predictive values and causal relationships are not yet established.

    • Conclusions:

    • Effective treatments exist for stroke caused by specific hematologic diseases.
    • Further research is needed to determine the predictive value and causality of hemostatic defects in stroke risk.